Form 4: Artiva Biotherapeutics Executive Christopher Horan Reports Stock Award and Disposal

Christopher Horan, Chief Tech Operations Officer at Artiva Biotherapeutics, reports the acquisition of 60,000 shares of common stock and disposal of shares.

Summary

• On February 26, 2025, Christopher Horan, Chief Tech Operations Officer of Artiva Biotherapeutics, acquired 60,000 shares of common stock.
• The acquisition was related to a restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.
• Horan also disposed of shares, resulting in a total of 85,000 shares beneficially owned following the reported transactions.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard reporting of stock transactions. The acquisition is a positive, but the disposal is a slight negative, balancing out overall.

Positives

• The acquisition of 60,000 shares by a key executive could be seen as a positive sign of confidence in the company's future.

Negatives

• The disposal of shares by the same executive could be interpreted negatively, although the specific amount disposed of is not detailed.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• Shareholders may be interested in the stock transactions of key executives as an indicator of company performance and confidence.

Key Dates